Potential mechanisms include the impact of high insulin resistance on the action of a drug which acts predominantly through potentiating insulin secretion, impaired GLP-1 secretion in obesity, or direct effects of lipotoxicity on GLP-1 receptor expression which have been demonstrated in animal models21–23. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.